PARTI Overview We are a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. GT-02287 - our lead product candidate, for the treatment of Parkinsons disease, is currently being evaluated in a Phase 1b study in people with Parkinsons disease ...
Q2 FY2026 — expected 2026-08-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-26 | 2025-12-31 | 0001104659-26-035188 | EDGAR | 96K words |
| 2025-03-27 | 2024-12-31 | 0001558370-25-003823 | EDGAR | — |
| 2024-03-26 | 2023-12-31 | 0001558370-24-003943 | EDGAR | — |
| 2023-03-23 | 2022-12-31 | 0001558370-23-004460 | EDGAR | — |
| 2022-03-25 | 2021-12-31 | 0001558370-22-004363 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-11 | 2026-06-30 | 0001104659-26-094048 | EDGAR | — |
| 2025-11-12 | 2025-09-30 | 0001104659-25-110347 | EDGAR | 27K words |
| 2025-08-12 | 2025-06-30 | 0001558370-25-011220 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001558370-25-007747 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001558370-24-015709 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001558370-24-011589 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001558370-24-008132 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001558370-23-019014 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001558370-23-014499 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001558370-23-009510 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001558370-22-017414 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001558370-22-012533 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-11 | 0001104659-26-094041 | EDGAR | — |
| 2026-07-16 | 0001104659-26-084086 | EDGAR | — |
| 2026-03-26 | 0001104659-26-035174 | EDGAR | 3K words |
| 2026-03-18 | 0001104659-26-029968 | EDGAR | — |
| 2026-02-03 | 0001104659-26-009747 | EDGAR | — |
| 2025-12-18 | 0001104659-25-122353 | EDGAR | — |
| 2025-11-28 | 0001104659-25-116947 | EDGAR | — |
| 2025-11-12 | 0001104659-25-110343 | EDGAR | — |
| 2025-10-14 | 0001104659-25-099343 | EDGAR | — |
| 2025-10-09 | 0001104659-25-098376 | EDGAR | — |
102 total filings indexed. 75 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001819411 |
| Ticker | GANX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.gaintherapeutics.com |
| Listed | 2021-03-18 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/GANX (~200 tokens, structured JSON with cryptographic provenance)